Date:10/25/2010

314,997Scientific & Industrial Imaging134,43478,934393,192238,914RF Technology185,991173,216522,911544,389Total$ 605,088$ 485,676$ 1,706,633$ 1,496,030Gross profit:Industrial Technology$   82,38351.1%$   62,06047.5%$
223,82550.6%$
90,50147.9%Energy Systems & Controls65,59053.1%52,46450.9%183,88452.8%164,12352.1%Scientific & Industrial Imaging82,61061.5%44,16956.0%238,42760.6%132,38555.4%RF Technology91,16649.0%86,82750.1%257,12549.2%264,71748.6%Total$ 321,74953.2%$ 245,52050.6%$
903,26152.9%$
751,72650.2%Operating profit*:Industrial Technology$   44,95427.9%$   30,54723.4%$
5,46226.1%$
91,61423.0%Energy Systems & Controls28,61123.2%19,21418.7%76,60622.0%59,92619.0%Scientific & Industrial Imaging31,19323.2%14,81818.8%88,32322.5%43,30018.1%RF Technology37,15520.0%38,91822.5%104,06019.9%115,72421.3%Total$ 141,91323.5%$ 103,49721.3%$
384,45122.5%$
310,56420.8%Operating profit excluding restructuring*:Industrial Technology$   44,95427.9%$   31,49424.1%$
5,46226.1%$
95,93124.1%Energy Systems & Controls28,61123.2%20,50319.9%76,60622.0%63,73920.2%Scientific & Industrial Imaging31,19323.2%15,19519.3%88,32322.5%44,79718.8%RF Technology37,15520.0%38,97622.5%104,06019.9%116,54221.4%Total$ 141,91323.5%$ 106,16821.9%$
384,45122.5%$
321,00921.5%Net Orders:Industrial Technology$ 169,887$ 125,776$
488,665$
391,049Energy Systems & Controls135,224104,593377,484298,551Scientific & Industrial Imaging152,49984,329418,874235,433RF Technology196,265184,243555,427534,251Total$ 653,875$ 498,941$ 1,840,450$ 1,459,284*  Operating profit is before unallocated corporate general and administrative expenses.  These expenses were $13,680 and $11,625 for the three months ended September 30, 2010 and 2009, respectively and $36,315 and $35,936 for the nine months ended September 30, 2010 and 2009, respectively.Roper Industries, Inc. and SubsidiariesCondensed Consolidated Statements of
'/>"/>

SOURCE Roper Industries, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Federal Funding Awarded to Test Antimicrobial Properties of Copper Metals
2. Mayo Clinic Study Finds FDA Warning Against Anti-Nausea Drug Droperidol Unnecessary
3. Dallas Researchers Find Compression Stockings Improperly Used
4. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
5. Cerenis Therapeutics In-Licenses Intellectual Property for New Treatment of Aortic Valve Stenosis
6. Intellect Neurosciences, Inc. Announces Independent Studies on Copper Binding Properties of its Lead Candidate OXIGON(TM)
7. B. Braun Medical Inc. to Demonstrate Infusion Systems Technologies at HIMSS 2009 Interoperability Showcase
8. Edifecs, CAQH and Harvard Pilgrim Health Care Will Examine CORE Phase II Testing Outcomes and Lessons Learned at HIMSS09 Interoperability Showcase
9. NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds
10. H3N2 Influenza Unlikely to Spread Between Humans, K-State Infectious Disease and Diagnostics Experts Say; Swine Exhibits at Fairs are Safe With Proper Hygiene
11. Enhanced Food Safety and Systems Interoperability the Themes of Food Traceability Interoperability Summit 2010